Clinical data of HIV-1–infected patients stratified according to the actual antiretroviral treatment regimen at the time of the study
| Patient group (Treatment) . | I (no therapy) . | II (2 RT inhibitors)† . | III (HAART)‡ . |
|---|---|---|---|
| N | 29 | 20 | 16 |
| Age (y) | 5 (0.5-28) | 7 (1-16) | 10 (2-21) |
| CD4 count (%) | 20 ± 2 | 23 ± 3 | 25 ± 2 |
| CD4 count (cells per μL) | 697 ± 87 | 977 ± 242 | 766 ± 143 |
| “Viral load” (log10 RNA copies per mL) | 4.54 (2.70-5.76) [n = 14]* | 4.81 (1.90-6.53) | 5.13 (1.48-5.87) |
| Duration of therapy (mo) | NA | 11 (7-20) | 10 (7-22) |
| Number of patients with “viral load” less than 3.0 log10copies per mL (%) | 2 (14) | 7 (35) | 7 (43) |
| Patient group (Treatment) . | I (no therapy) . | II (2 RT inhibitors)† . | III (HAART)‡ . |
|---|---|---|---|
| N | 29 | 20 | 16 |
| Age (y) | 5 (0.5-28) | 7 (1-16) | 10 (2-21) |
| CD4 count (%) | 20 ± 2 | 23 ± 3 | 25 ± 2 |
| CD4 count (cells per μL) | 697 ± 87 | 977 ± 242 | 766 ± 143 |
| “Viral load” (log10 RNA copies per mL) | 4.54 (2.70-5.76) [n = 14]* | 4.81 (1.90-6.53) | 5.13 (1.48-5.87) |
| Duration of therapy (mo) | NA | 11 (7-20) | 10 (7-22) |
| Number of patients with “viral load” less than 3.0 log10copies per mL (%) | 2 (14) | 7 (35) | 7 (43) |
Group I had no specific antiretroviral therapy, group II had at least 6 months of treatment with 2 nucleosidic inhibitors of HIV-1 reverse transcriptase (RT inhibitors), and group III had at least 6 months of treatment with 2 RT inhibitors and at least 1 inhibitor of HIV-1 protease (HAART). Sixteen patients were studied before and after changes in their therapeutic regimen and were included in both respective patient groups; 4 patients were studied repeatedly and were included in all 3 groups. The remaining 21 patients were studied only once. Data are given either as median values (range) or as arithmetic mean ± SEM.
AZT indicates zidovudine; d4T, stavudine; ddC, zalcitabine; ddI, didanosine; 3TC, lamivudine; IDV, indinavir; NFV, nelfinavir; SQV, saquinavir; RTV, ritonavir; and NA, not applicable.
Plasma viral load levels were not available for all patients; the actual number is given in brackets.
Specific drug combinations: 9 patients received AZT + 3TC; 8, AZT + ddI; 2, AZT + ddC; and 1, d4T + 3TC.
Specific drug combinations: 3 patients received d4T + 3TC + IDV; 4, d4T + ddI + NFV; 3, d4T + 3TC + NFV + SQV; 1, d4T + 3TC + NFV;1, AZT + 3TC + NFV; 1, AZT + ddI + IDV; 1, d4T + NFV + SQV; 1, d4T + ddI + NFV + SQV; and 1, d4T + ddI + RTV + SQV.